Zhuhai Kerui Biotechnology: difference between revisions
Diff·revision 23 → 24·23:50, 6 Sep 2025
Difference between revision 23 and revision 24 of Zhuhai Kerui Biotechnology. 2 lines changed; the page grew by 205 bytes.
| Revision 23 — 13:28, 30 Aug 2025 SecondarySrc_Seb (talk) de-orphan 6,822 bytes ±0 | Revision 24 — 23:50, 6 Sep 2025 Compounding_Cate (talk) ce 7,027 bytes +205 | ||
|---|---|---|---|
| 47 | | Raw materials and oils | Bulk | Certificate, limited detail | | 47 | | Raw materials and oils | Bulk | Certificate, limited detail | |
| 48 | 48 | ||
| + | 49 | Method disclosure on the peptide lines is the distinguishing documentation feature. It does not make the figure correct; it makes it checkable, which is a different and more useful property.{{r|usp1503}} | |
| + | 50 | ||
| 49 | == Independent testing record == | 51 | == Independent testing record == |
| 50 | Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r|reports}} | 52 | Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r|reports}} |